Bio Pharma Dive
MARCH 20, 2024
The company claims its approach could yield more effective and safer T-cell engagers, a type of cancer medicine that’s attracted significant interest from drugmakers in recent years.
Pharmaceutical Technology
MARCH 20, 2024
Johnson & Johnson has received approval from the FDA for EDURANT PED to treat human immunodeficiency virus-1 (HIV-1) in children.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 20, 2024
Brain scans of a 72-year-old man diagnosed with a highly aggressive form of cancer known as a glioblastoma have revealed a remarkable regression in his tumor’s size within days of receiving an infusion of an innovative new treatment.
Bio Pharma Dive
MARCH 20, 2024
Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 20, 2024
Rustom Lawyer, co-founder & CEO of Augnito, a leading voice AI solutions provider, has unveiled profound insights into the potential of voice artificial intelligence (AI) in healthcare. Emphasizing its transformative role, Lawyer shed light on how voice AI is reshaping the landscape of healthcare, empowering a new generation of healthcare professionals – the ‘superclinicians.
Bio Pharma Dive
MARCH 20, 2024
The biotech, which raised $540 million in an initial public offering last year, is pitching the medicine as a potential challenger to Amgen’s blockbuster eye drug Tepezza.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
MARCH 20, 2024
The high-profile startup, co-founded by CAR-T innovator Carl June, will use the funds to bring an autoimmune disease treatment into proof-of-concept studies.
Pharmaceutical Technology
MARCH 20, 2024
The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis (GPP).
Pharma Times
MARCH 20, 2024
Rare kidney diseases are a group of conditions which account for over 5% of people living with chronic kidney disease
Fierce Pharma
MARCH 20, 2024
Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. Sales came to 1.5 billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1 billion) for 2023, coming up short of expectations.
Pharmaceutical Technology
MARCH 20, 2024
At the data cutoff (July 2023), 7 out of 11 patients (64%) treated with Aphexda achieved a partial response (PR), with 5 of them (45%) confirmed as PRs.
Worldwide Clinical Trials
MARCH 20, 2024
In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial. As the study of how an individual’s genes affect their response to drugs, pharmacogenomics is a critical factor in developing effective and safe drugs and dosages in clinical trials. 6 Ways Pharmacogenomics Helps Your Clinical Trial Enhances Drug Safety PGx a
Pharmaceutical Technology
MARCH 20, 2024
Cellectis presented promising data with UCART20x22, which represents a pioneering allogeneic dual CAR T-cell product designed to target two established antigens.
Fierce Pharma
MARCH 20, 2024
After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have | After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
MARCH 20, 2024
Jemperli could bring about a transformation in the standard of care, offering hope to microsatellite high (MSI-H) rectal cancer patients.
BioSpace
MARCH 20, 2024
As part of a sweeping reorganization, Bayer Pharmaceuticals on Wednesday shuffled its leadership roster, which included the creation of a new unit and role changes for its executives.
Pharmaceutical Technology
MARCH 20, 2024
The past, current, and future efforts in treating cancer were discussed on day one of ELRIG UK conference in Manchester, UK.
pharmaphorum
MARCH 20, 2024
Understanding the employee experience in healthcare is essential for improving the patient experience. Learn more about the importance of employee experience in healthcare and how it impacts patient care.
Pharmaceutical Technology
MARCH 20, 2024
In this issue: Studying novel obesity drugs, pharma prepares for climate disasters, the CRISPR pipeline accelerates, and more.
Fierce Pharma
MARCH 20, 2024
As two of the world’s largest pharmaceutical companies, Johnson & Johnson and Pfizer have long been rivals in various therapeutic areas. | The company is accusing former employee Andrew Brackbill of downloading thousands of confidential strategy-related files before leaving for rival Pfizer.
Pharmaceutical Technology
MARCH 20, 2024
Croda International has entered a collaboration agreement with the AAHI to innovate and develop vaccine adjuvant formulations.
Fierce Pharma
MARCH 20, 2024
After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
MARCH 20, 2024
Everest Medicines has received approval from the Singapore Health Sciences Authority (HSA) for NEFEGAN to treat primary immunoglobulin A nephropathy (IgAN) in adults at disease progression risk.
pharmaphorum
MARCH 20, 2024
Discover how AI is being utilised in the fight against antimicrobial resistance (AMR), particularly in addressing MRSA infections.
Pharmaceutical Technology
MARCH 20, 2024
TB is the leading determiner of death in patients with HIV, yet while new drug research is underway, funding and accessible treatments remain distant.
Pharma Times
MARCH 20, 2024
In 2021, neurological conditions, including Alzheimer's disease, affected approximately 3.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
MARCH 20, 2024
Vicore gets FDA breakthrough status for Almee, a cognitive behavioural therapy (CBT) digital health therapy used to support people with pulmonary fibrosis
Fierce Pharma
MARCH 20, 2024
Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. | Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after its Opdivo monotherapy setback five years ago and a subsequent market withdrawal.
XTalks
MARCH 20, 2024
In this featured episode of Xtalks People in Life Sciences, Ayesha spoke with Ashish Jain, Senior Director of Clinical Safety and Pharmacovigilance (PV) at Curis , a pioneering biotech company specializing in cutting-edge cancer therapies. Jain shared his journey into clinical safety and PV, highlighting key milestones along the way. Delving into his daily work at Curis, he revealed his strategies for prioritizing tasks and staying informed of the latest developments in PV.
pharmaphorum
MARCH 20, 2024
Orchard Therapeutics has revealed the US price of Lenmeldy, its gene therapy for rare disease MLD, placing a $4.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
297 
Let's personalize your content